Marijuana Compound May Reduce Seizures in Severe Epilepsy

Warning message

The subscription service is currently unavailable. Please try again later.

A new study shows a mean reduction in seizures of over 50% in 3 months among some patients with epilepsy taking cannabidiol (CBD).

Results of an open-label, multicenter trial of a liquid product that is 99% cannabidiol (Epidiolex; GW Pharmaceuticals), the major nonpsychoactive ingredient in marijuana, showed that treatment provided seizure relief in children with Dravet syndrome and Lennox-Gastaut syndrome (LGS) who had been resistant to at least eight antiepileptic drugs.

"I think this is an important study," and it's "definitely the largest" study of a pure medical marijuana product, commented lead investigator Orrin Devinsky, MD, director, New York University (NYU) Epilepsy Center, and professor, neurology, NYU. "It looks very, very promising but until we get blinded data, we have to be humble," he said.

The full results will be presented next week during the American Academy of Neurology (AAN) 67th Annual Meeting.

Uncontrolled Seizures

CBD is a component of...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.

URL: 
http://www.medscape.com/viewarticle/843073